# US 2021/0171945 A1 · Methods of modulating antisense activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171945 A1
- Document ID: US20210171945A1
- Status: Published application
- Kind: A1
- Application number: 16/762,734
- Filed: 2018-11-16
- Published: 2021-06-10
- Earliest claimed: 2017-11-17
- Assignees: Ionis Pharmaceuticals, Inc.
- Applicants: Ionis Pharmaceuticals, Inc.
- Inventors: Xue-hai Liang; Stanley T. Crooke
- Web page: https://patentgrep.com/patent/US20210171945A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C12N 2310/11: Antisense
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/341: Gapmers, i.e. of the type ===---===
- C12N 2320/31: Combination therapy
- C12N 2320/50: Methods for regulating/modulating their activity
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein are methods for increasing antisense activity by modulating translation. In certain embodiments, a compound comprising an antisense oligonucleotide is co-administered with an inhibitor of translation.

## Claims

### Claim 1

A method comprising
contacting a cell with an antisense compound comprising an antisense oligonucleotide, wherein the nucleobase sequence of the antisense oligonucleotide is complementary to a target mRNA and
contacting the cell with an inhibitor of translation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the expression of the target mRNA is reduced.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the amount of the target mRNA is reduced.

### Claim 4 (depends on 3)

The method of claim 3, wherein the amount of the target mRNA is reduced to a greater extent than the amount of target mRNA reduction that occurs in the absence of the inhibitor of translation.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any of claims 1-4, wherein the target mRNA is efficiently translated in the absence of the inhibitor of translation.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any of claims 1-5, wherein the target mRNA is enriched in polysomes in the absence of the inhibitor of translation.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any of claims 1-6, wherein the target mRNA is enriched in heavy polysomes in the absence of the inhibitor of translation.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any of claim 1-7, wherein the target mRNA is not IL-4 receptor, IL-13 receptor, a subunit of an IL-4 receptor, or a subunit of an IL-13 receptor.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any of claims 1-8, wherein the nucleobase sequence of the antisense oligonucleotide is complementary to the coding region of the target mRNA.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein the nucleobase sequence of the antisense oligonucleotide is complementary to a portion of the target mRNA that is accessible during translation.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the nucleobase sequence of the antisense oligonucleotide is at least 80% complementary to the target mRNA.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the nucleobase sequence of the antisense oligonucleotide is at least 85% complementary to the target mRNA.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the nucleobase sequence of the antisense oligonucleotide is at least 90% complementary to the target mRNA.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the nucleobase sequence of the antisense oligonucleotide is at least 95% complementary to the target mRNA.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the nucleobase sequence of the antisense oligonucleotide is 100% complementary to the target mRNA.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any of claims 1-15, wherein the antisense oligonucleotide is a modified oligonucleotide.

### Claim 17 (depends on 16)

The method of claim 16, wherein the modified oligonucleotide is a gapmer.

### Claim 18 (depends on 16, 17)

The method of claims 16 or 17, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one modified internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 20 (depends on 18)

The method of claim 18, wherein all of the internucleoside linkages of the antisense oligonucleotide are modified internucleoside linkages.

### Claim 21 (depends on 20)

The method of claim 20, wherein all of the internucleoside linkages of the antisense oligonucleotide are phosphorothiate internucleoside linkages.

### Claim 22 (depends on 19)

The method of claim 19, wherein all of the internucleoside linkages of the antisense oligonucleotide are selected from phosphorothioate and phosphate internucleoside linkages.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any of claims 1-22, wherein the antisense compound is single-stranded.

### Claim 24 (depends on 23)

The method of claim 23, wherein the antisense compound consists of a conjugate group and the antisense oligonucleotide.

### Claim 25 (depends on 24)

The method of claim 24, wherein the antisense compound consists of the antisense oligonucleotide.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 1-25, wherein the inhibitor of translation inhibits translation intiation.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 1-25, wherein the inhibitor of translation inhibits translation elongation.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 1-25, wherein the inhibitor of translation is a second antisense compound comprising a second antisense oligonucleotide.

### Claim 29 (depends on 28)

The method of claim 28, wherein the nucleobase sequence of the second antisense oligonucleotide is complementary to the 5′-UTR of the target mRNA.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the second antisense oligonucleotide is a modified oligonucleotide that is not a gapmer.

### Claim 31 (depends on 30)

The method of claim 30, wherein the second antisense oligonucleotide is a fully modified oligonucleotide.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 1-27, wherein the inhibitor of translation is a small molecule.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32)

The method of any of claims 1-27 or 32, wherein the inhibitor of translation is Rapamycin, Everolimus, Temsirolimus, Ridaforolimus, Hippuristanol, or Homoharringtonine.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32, 33)

The method of any of claims 1-27, 32 or 33, wherein the inhibitor of translation is puromycin.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32)

The method of any of claims 1-27, 32, or 33, wherein the inhibitor of translation is cycloheximide.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32)

The method of any of claims 1-27, 32, or 33, wherein the inhibitor of translation is 4E1Rcat.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 32)

The method of any of claims 1-27, 32, or 33, wherein the inhibitor of translation is lactimidomycin.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any of claims 1-37, wherein the inhibitor of translation inhibits eukaryotic translation.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any of claims 1-38, wherein the cell is in a population of rapidly proliferating cells.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 1-39, wherein the cell is a tumor cell.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 1-40, wherein the cell is in an animal.

### Claim 42 (depends on 41)

The method of claim 41, wherein the animal is a human individual.

### Claim 43 (depends on 42)

The method of claim 42 comprising administering the antisense compound and the inhibitor of translation to the individual.

### Claim 44 (depends on 43)

The method of claim 43, wherein the individual has a disease or condition that is ameliorated or treated by the administration of the antisense compound.

### Claim 45 (depends on 44)

The method of claim 44, wherein the disease or condition is cancer.

### Claim 46 (depends on 43, 44, 45)

The method of any of claims 43-45, wherein the antisense compound and the inhibitor of translation are administered simultaneously.

### Claim 47 (depends on 43, 44, 45)

The method of any of claims 43-45, wherein the antisense compound and the inhibitor of translation are administered sequentially.

### Claim 48

Use of an antisense oligonucleotide with a nucleobase sequence complementary to the coding region of a target mRNA in combination with an inhibitor of translation for treatment of a disease.
